OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2025-12-31-accounts

i'4F LUNG CANCER RESEARCH (CHARITY COMMISSION NO. 1201017) ACCOUNTS 31 DECEMBER 2025

LUNG CANCER RESEARCH (CHARITY COMMISSION NO. 120101T) ACCOUNTS FOR THE YEAR ENDED 31 DECEMBER 2025 CONTENTS PAGE Trustees, Re Aco)untants' Report Independent Examiners Report Balance Sheet Statement of Finandal Activitles Notes to the Accounts 10

LUMG CANCE.R RE$LARCH (CHARITY COMMISSION NO, 1201017) TRUSTEÉS. RE.PORT FOR THE YeAA FNDED 31 DECEMBER 2029 12Q1017 Prlndfml Addr••• lo Krtyfjtm Ro•va• LLP. 168 6tK¥vJU) HW 3tr••L 2r￿ FtrA. E1 Sellerh￿l f)é•J datsd 20th Januwy 2 How Consthulod Ao 8 tru81 ObJ•rt• of ChArfty •••8ts ar8 IWd CMJ trusl to fw)d dmlcal laboratrAy and of Lung CarKar. In 8etkng (xff (tycbv80 8nd rA8nnlng ow activrtkn8 the Tn have gfrv￿ rAreful c￿￿1d￿011￿ to ts Chtrty CcYM￿SkrfI 98neral guthrKe PJbI￿ berrf Accountants Kr88ton ReAves LLP 2nd Flw, 168 SI￿X￿j11jth HW Street L￿d(￿l E16RA Bankw• HSBC Bank F4c 12 Hampstead High Street Hampstead NW3 1PY TrusZ• Robln EllisM [retIr￿ 17th Felyuary 2025) Ajastaw Meeks NiCC4 Wytyyn Tn￿l•• S•l•ctlon IS310N STATEMEHT Infroductlon L£mg Carw A￿0￿ch wa3 estsb1i￿I ￿ a red (rnglGlW￿] dHty fxKnter.1101823) k> sipr<Mt ts ￿earch n Ihe fE&J ¢arKw. th 15th N<￿eMb& 2022, L Cancff Rewrth becanw a regtered CIO (¥efdtf¥J LndAf tt• fxmbef (1201017) tr￿£6￿1 10 R£th Ellkni {retTrd 17th Fetxiw 2tr25) Pr(rfassor Seckl MS NI￿ WytK

LUNG CANCER RESEARCH (CHARITY COMMISSION NO. 1201017) TRUSTEES. REPORT FOR THE YEAR ENDED 31 DECÉMBER 2026 Purpos• The htentlon of the ch8rlty 16 to 8UPPOrt research In Iho fleld of lung cancer whlch Is n17W 8howlng 81gn8 of swnincant dinic81 advances. One of the (xiginal purposes, to raise funds to support cla88 actlon litlgation tha proceeds of whlch were to be usod for the purposes of research (followlng 81mi18r oxperlence In tho united Stales) has nLM been suspended after thanges In Engllsh18w and pracllce. Hlstory The tharlty ben8fft3 frDm lega¢les, and although the pollcy at present Is not to actlvely ralse funds dlrect frtxn the public, the d￿rity does benefft from publlc donation8. In March 2021, a grant appllcation from Professor Seckl was approved by the trustees (after extemal peer revlew) for resea￿ tsrgeting the activity of the klnase RSK4 and its downstream medlator8 as novel therapeutlc 8trategles for lung cancer. The research requlred the recxuitrnent of one post-doctoral research associate for four yearn and one PhD student for three and a half years. A grant of £430,000, to be pald over 4 years, was awarded. A one year in advance payment was made In August 2021 for £107,500 and thls has been shown In the accounts accortlingly. Th8 Lung Cancer Research Charity (LCRC) has been supportlng two projects one lead by Dr Ollvler Pardo Dr Pardo's work fc4low8 on frDm the discovery that 8 moleojle In lung cancer cells called RSK4 (a klnase) is a crftlcal mediator of reslstsnce to existing treatments as well as enabllng cancer cells to spread to other parts of the body a process called meLgstssis. In this prior work published In a leading sclentlflc Joumal called Sci Trdnslational Medlcine In 2021, Dr Pardo's team were able to show that RSK4 could be Inhlblted both ganetlcalty and by drugs to reverse reslstance to exlsting treatments and prevent metastssls. As we ncm ffK)ve to estsblish a trial testing our RSK4 tsrgeting drugs it remalns Important that we understsnd rnore about the blology of RSK and how it mlght become reslstant to our drug treatrnents. Therefore, in work supportod by the LCRC, his team have Investigated the moleajlar mechanlsms through whlch RSK4 Is Involved tn promob'ng lung cancer progresslon and focused ￿ two separate pathways that were identlfiad as altered by this kinase: glucose metsbolism and DNA damage responsa. For gluo)se metabolism. hls team found that Inhlbltlon of RSK4 to restrlct lung can￿r viablllty trlggered a metatx)lic rescue response, where cells Increased their usage of glucose though glycolysls coupled to the Trl Caboxyllc Acld (TCA) cyde. This enabled the cancer cells to try and survfve the loss of RSK4 and Involved a p9eud￿hYp0xIC response that promoted the expresslon of metatx)lic enzymes drivlng the increased use of glucose. Our prelimlnary experlments suggest that Inhibfting this metsbollc adapts￿on together wlth RSK4 would be synerYJlstic and lead to more efficlent killing of lung cancer cell8. F(x DNA damage response, Dr Pardo's team were able to show that RSK4 inhlbitlon Is accompanied by DNA damage and this may be tnggered by the interaction of RSK4 with an enzyma Involved In nudeotide synthesis, CAD. Conversely, hls team demonstrated that DNA damage triggered an upregulatlon of RSK4 expresslon. demonstrating that thls kinase Is part of a pro4urvival response that enables the cell to survlve the stress of chemotherapeutic drug treatmenL We are now testing how comblnlng RSK4 wlth CAO Inhlbition, or 1nhlblt1￿ of DNA repair enzymes, may be Synerglstlc In our survlval assays. Hence. our work so far has Idenbfied novel therapeutic combinations thal are currently being validated and If posltive will result In further improvements for lung cancer patlent outcA)mes In the dlnlc.

LUNG CANCER RESEARCH (CHARITY COMMISSION NO. 1201017) TRUSTEES, REPORT FOR THE YEAR ENDED 310ECEMBER 2025 Dr C3horunf8 toam havg t￿n uslng the LCRC fuiidB to 8UW)L¥t samplo colleclion wrthln the Nallonal Instllute of Health R9888rch REFINE-Lung 8tudy. Th19 tr18118 t8Stlng ￿ether wo can 8afely reduce Ihe frtwuoncy of glvlng the oxlromely oxp8nslve Immunotherapy agont pembrollzum8b for lung cancer P8tlents. If posltlve. the tr181 wlll Save Iho NHS up to 8 bllllon poiinds per year. However, the NIHR does not cover 63¢ mplo collectlon and rese8rch based on Ihe8e sampleg. The LCRC funding Is fortun8tely enabling us to colloci bl(YJd 88mp108 80 that We C8n188rn wllhln the trlal how to bettar select patlent8 for Immunotherapy tre8tments whlch only help about 25% of the lung cancer patlent8 who recelve rt although all Indivldu818 wlll 8tsrt Ihls Iherepy. The LCRC18 paying for UK hospltal site8 to take blood8, record cllnlcal Informatlon 8nd send blood 8ampl88 8nd tl88ue8 to our centre 8t Imperlal College. The funds also support tho proce88ing and banklng of these 88mples. We have been focused on sample collectlon and storage, bul have a160 been runnlng pilot flow cytometry experiments to develop a novel PD-1 receptor occupancy 8880y that we Intend to run on banked samples now that we are approachlng the Interlm analysls of thls largo natlon81 lung cancer trlal. We wlll also be runnlng more Immune fluorescence on the tlssue blocks and contlnue to work with digltal pathology collaborators on developlng 8 novel blomarker approach. The results of thls work 8hould Improve patlent stratificatlon to the most appropriate theraples. reduce patient toxlcity. Improve patlent qU811ty of life and help save the NHS tlme and money. Th• Trustees Professor Elllgon Robln Elllson Is a pradislng sollcltor and 8cademlc. Ha speclallses In the development of pensions and rclated flnancial services products for Insurers and other providers, and in European and intematlonal penslons, pen8lons trustee law and penslons In matrimonlal matters. He acts for a number of foreign govemments and government agencles. He18 8 founder of several companles. Including Pendragon Professional Information, publisher of Perspective, the electronic regulatory and legal publisher to the pensions Industy, and of the London & Colonial insurance group. and is trustee of several penslon funds, (induding those of Cambridge Colleges and Publlc Servlce Pension Fund) tx)th as independent trustee and as chalmian. He also practlces as a commercial mediator, and was Chalrman of amongst others the Really Useful Theatres and the Carlllion . penslon schemes, and gave evklence to the Work and Penslons Select Commlttee followlng the collapse •" of Carflllon. ;' He was 8 founder of the Association of Pensions Lawyers, belng awarded Its Wallace Prize in 1995 and in *' 1997 he was elacted the first sollcitor Honorary Fellow of the Pensions Management Institute. He was .?;; awarded the Industry Achlevement aw8rd by Portfolio Instltutlonal In 2013 and was European Penslons 4A Personalty of the year in 2017. . H8 Is the 8Uthor of numerous t)ooks on penslons Includlng a four volume loose-leaf Penslons Law and Practlce. (Sweet & Maxwell), the Pension Trustees Handbook (7th ed, 2013, Thorogood) and Is editor of '" P8nslons Beneflts L8w Reports. HIS book, Penslon Fund Investment Law, was published by Bloomsbury :1.; PrDf8sslonal in 2008, and he c(>authored Pensions and Divorce (Lime Legal) publlshed In 2010. His more ,-}' recent b￿ks, Pensions for you and your business, (Crimson) and Halsbury's Laws Volume 80: Pensions (8uttefWOrths) were publlshed in 2013, and his study of regulation Red Tape: managing excess In law, regulatlon and the courts was publl8hed by Cambrldge University Press In 2018. He wrote a monthly ¢:.. ¢￿UMn on pen.8lons law for Pensions World for foty years. ri He Is a Wisltlng Professor in Penslons Law and Economics at Cass Buslness School, Cty, Universlty of London, and an occaslonal broadcaster on radlo and lelevislon on penslons matters. He Is a former Chairman of the Penslons and Lifetlme Savings Associatlon (formerly the Nats'onal Assodation of Pension 'V:' Fund8) and has particular experience In chaimianshlp, trusteeship, corporate govemance, relatlonships '- wlth regulatory bodles, the law of penslons, insurance and financial servlces, and negotiatlon and dlspute r8solut!on..&:.

LUNG CANCER RESEARCH (CHARITh COMMISSION NO. 1201017) TRUSTEES, REPORT FOR THE YEAR ENDED 310ECEMBER 2026 Alastair M•eks astsir Meeks is a rntired 801icltor. Until May 2020 he was a partner in Pinsenl Mason8 and practised Pensions law. He was chair of the Assocaatson of Pension Lawyers from 2007 to 2009 and is a Fellow of the Pensions Management Instrtute. He aded in relation to many landmark pension cases, including the ITN case and BESTrustees v Stuart, both of Wh￿ explored the interaction between explanatory literature and trust documentstion. He acted fi)r the tTUStees of Ar￿10 United Pension Scheme and the Dexion Scheme, and in the process helped prompt the eStab1￿hrnent of the DWP'S Financial Assistance Scheme. He is the author of Tolleys Pensions Cases, the definitive work on the subject and currently edrts the pensions cases section of Tolley's Pensions Law. Since October 2023 he has acted as a professional trustee with ZEDRA Govemance Limited. Professor Seckl Michael Seckl, MD, PhD, Fmedsci trained medicine and science at University College London (United lfjngd￿) obtaining a Bsc in immunology in 1983 and his MBBS in 1986. He did his general professional sP￿all$l medical oncology training on the London circuit, and became a fellow of the Royal College PhyS￿lanS. He obtained his PhD in biochemistry in 1995 from the London Research Institute (now as the CRICKyUniversty College London and was that year appointed as a senior lecturerlhonorary consultant in medical oncology at Charing Cross Hospital in London, now part of Imperial lege London. then established his own research groups working on cell signalling in lung cancer and trophoblastic rs supported by grants from Cancer Research UK, the Medical Research Council, Wellcome Trust, g, industry, and others. He was promoted to reader in 2002 and professor of molecular oncology CYJ4, hthen he also took on the directorship of the Charing Cross Gestational Trophobla8ts'c Disease and the 8upraregional Tumour Marker Assay Service. Seckl also leads the Imperial Cancer Trials unit, runs the London Lung Cancer Alliance, has run iple Phase 1-111 trials, and previously ran the Imperial College Experimental Can￿r Medecine Centre 2(X)7-2023. He 18 on the editorial board of several journals and chairslsits on several grants ee8. He is the immediate past-president of the Royal Society of Medicine Oncology section and n Organisabon for the Treatment of Trophoblastic Disease. He was also past president and is the t treasurer of the Intemabonal Society for the Study of Trophoblastic Disease and holds an honorary hip with the Peking Union Medical College in China. He also established and now co4eads the "cal can￿r domain wrthin the European Rare Adult Cancer Network (EURACAN). Uy, he was director of postgraduate studies for the Department of Surgery and Cancer with responsibllty for 2(X) MScJMRes and 400 PhD students between 2012- 2022. own research group, he and his team have ￿1Ved numerous national and intemational and in the past 5 years have raised over £18M of grant income. He has published over 280 peer manuscnpts many appearing in leading scientific and medical joumals such as Lancet. Lancet loqy, New England J of Medicine, Nature communications, Science Translational Medicine and J OfKnbgy. In ￿CognItion for his contributions to frEdical science and his internatlonal leadership he a Fellow of the Academy of Medical Sciences in 2017. He remains committed to teaching, , and his patients.

LUNG CANCER RESEARCH (CHARITY COMMISSION NO. 1201017) TRUSTEES. REPORT FOR THE YEAR ENDED 31 DECEMBER 2020 Nlccl Wybom Ni￿1 Wybom 18 a Client D6rector at Videll Limited, with exten81ve experiencé In penolon •cheme governance, trustee 8eNices and 8trateglc over8ighl acr088 a broad range of defined bonafit (DB) and defined contrlbution (DC) pension arrangement8. She work8 c108ely with tru8tee board8, 8pon80r8 and advisers to support the effectNe management of pengion 8chemes, with a partlcular focu8 on governance, regulatory compllance, board effectivenes8 and member outcA>me8. Having worked In the pensions industry for over two decade8, Nie£i ha8 developed a 8trong reputation for delivering pragmats'c governance solutions and building trusted relatlon8hip8 With 8takeholder8 Her expenence spans schemes of varying 6izes and complexrty, including large-8cale DB and hybrid arrangements. Outside of her professional role, Nicci has a personal connection to the work of the charity Following surgery for a carcinoaid lung tumour in 2018, 8he has first-hand appreciation of the importance of research, treatrnent and 8UPPOrt services funded by the charity, and 18 pas8ionate about contn'buting to its ongoing Success and impact. I dedare that in my capacity of charity trustee, that: - the Trustees have approved the report above; and - have authorised me to sign it on their behalf. Alas Trustee Meeks

LUNG CANCER RESEARCH (CHARITY COMMIS810N NO. 1201017) ACCOUNTANTS. REPORT FOR THE YEAR ENDED 31 DECEMBER 2025 In accordan￿ with the engagement letter of 3 September 2013 we have prepared the accounts, set out on page8 8 to 10, from the accounting records of the Trustees and information and explanations given to us. These accounts have been compiled in accordance with the accounting policies set out in Note 1 to these accounts, These accounts are not intended to comply fully with the provisions of'UK Generally Accepted Accounting Principles,. This report is made to the Trustees of Lung Cancer Research Trust, in accordance with the terms of our engagemenL Our work has been undertaken so that we might prepare the accounts, report that we have done so and state those matters which we feel should be drawn to the Trustees, attention and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone, other than the Trustees, for our work or for this report. We have carrled out this engagement in accordance with technical guidelines issued by the Institute of Chartered Accountants In England & Wales and by the Society of Trust and Estate Practitioners. We have compiled this report with ethical guidance laid down by those bodies. We have not been instructed to cary out an audit of these accounts. For this reason, we have not verified the accuracy or completeness of the accounting records or infomation and explanations given to us and we do not, therefore, express any opinion on these accounts. Kreston Reeves LLP 2nd Floor 168 Shoreditch High Street London E16RA ACCOUNTS APPROVAL CERTIFICATE We approve these accounts and confimi that we have made available all relevant records and inf0m￿tIOn for their preparation. Alastair Meeks Michael Seckl Nicci Wbom

LUNG CANCER RESEARCH (CHARITY COMMI88ION NO. 1201017) BALANCE 8HEET A8 AT 31 DECEMBER 2020 UNRESTRICTED FUNDS UNRESTRICTED FUNDS 31 Dec•mb•r 2026 31 Dec•mbor 2024 Noto Curr•nt ass•ts HSBC Bank PIC 298,766 340,966 Total cash funds 2g8,766 340,966 Creditors withln ono year Accountancy charges Independent Examination charges 4,920 1,800 4,200 900 ,10 Net assots 29 33 ,86 Funds of th• Charlty Cash funds brought forward, 31 December 2024 Net receiptsl(payments) during the year 335,868 (43,820) 366,020 (30,154) Total funds ,046 33 66 Slgned by the Trustees on.,. ..15.. 04-.osm..zo¥ Alastair Meeks duly authorised to sign on behalf of all Trustees

LUNG CANCER RESEARCH (CHARITY COMMISSION NO. 1201017) STATEMENT OF FINANCIAL ACTIVITIES (SOFA> FOR THE YEAR ENDED 31 DECEMBER 2026 UNRESTRICTED FUNDS UNRESTRICTED FUNDS 31 Dec•mb•r 2026 31 December 2024 Not• Incoming resources Donations received 39,799 67,744 Total incomlng resources 39 799 67 744 Resources expended Accountancy charges Independent Examination charges Bank charges Imperial College for funding for lung cancer research Administration Expenses Registration with the Fundraising Regulator 2,820 900 53 79,174 552 120 2,100 900 116 94,496 286 Total resources expended 83,61 ,898 Net movement In funds (43,820) (30,154> Total funds brought hrward, 31 December 2024 335,866 366,020 Total funds as at 31 December 2026 29 33 ,866

LUNG CANCER RESEARCH (CHARITY COMMISSION NO. 1201017) NOTE8 TO THE ACCOUNTS FOR THE YEAR ENDED 31 DECEMBER 2025 Accounting pollcles Provision is included for all known current liabilitie& Contingent and future liabilities are not included, except where mentioned below by narrative note. Assets are shown at their value at the balan￿ sheet date. Income Tax (IT), Capital Gains Tax (CGT) and Inheritance Tax (IHT) The trust, as a charity, is exempt from IT and CGT on its investrnent income and capital gains. None of the restrictions on this relief, imposed by tax legislation, apply for this year. The trust is also exempt from IHT while its funds continue to be held or applied for charitable purposes. 3 Donations The Trustees received the following donations during this year.- 2025 2024 Multiple payments Charibes Trust Charitable Giving Charities Aid Foundation Paypal Giving Fund Just Giving Memory Giving Other 632 40 50 7,769 28,002 745 80 275 24,592 221 3,991 3,245 Single payments Donatis 61 303 Legacles from estates Christine Bellamy 37,537 39,799 67,744 10

LUNG CANCER RESEARCH (CHARITY COMMISSION NO. 1201017) INDEPENDENT EXAMINER'S REPORT FOR THE YEAR ENDED 31 DECEMBER 2025 I report on the accounts for the year ended 31 st December 2025 which are set out on pages 8 to 10. Res ctlve Res nslbllltles of Trustees and Examlner The charity's trustees are responsible for the preparation of the accounts. The charty's trustees consider that an audrt is not required for this year under section 144 of the Charibes Act 2011 (°the Chanties Acf) and that an independent examination Is needed. It is my responsibility to. - examine the accounts under section 145 of the Charities Act, - to follow the procedures laid down in the general Direcbons given by the Chanty Commission (under section 145(5)(b) of the Charitses Act, and - to state whether particular matters have come to my attentson. Basls of Examlnerfs Re ort My examination was carried out in accordan￿ general Directions given by the Chanty Commission An examination includes a rewew of the accountsng records kept by the charity and a comparison of the accounts presented those records It also includes considerabon of any unusual items or disdosures in the accounts, and seeking explanabons from the trustees con￿mIng any such matters. The procedures undertaken do not provide atl the eviden￿ that would be required in an audit, and consequently no opinion is given as to whether the accounts present a 'true and fairf view and the report is limited to those matters set out in the statement below. Inde ndent Examlner's Re In connection my examinatson. no matter has come to my attention:_ Vvhich gives me reasonable cause to believe that in any material ￿Pect the requirements - to keep accountsng records in accordance with Secbon 130 of the Chants'es Act and - to prepare accounts which accord with the accounting records and to comply with the accounb.ng requirements of the Charities Act have not been met; or to which. in my opinion, attentson should be drawn in order to enable a proper understarKJing of the accounts to be reached. 1911012026 Jery Canny FCCA, CPA Canny & Assoclates Chartered Cerufied Accountants 60 Cannon Street London EC4N 6NP Date